Which has preferable valuation and earnings, BHVN or MNPR?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$5.67 N/A Monopar Therapeutics N/A N/A -$13.72M -$1.90 N/A

Is BHVN or MNPR more profitable?

Monopar Therapeutics' return on equity of -12.84% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -866.46% -137.99% Monopar Therapeutics N/A -12.84% -12.57%

Does the media favor BHVN or MNPR?

In the previous week, Biohaven had 1 more articles in the media than Monopar Therapeutics. MarketBeat recorded 3 mentions for Biohaven and 2 mentions for Monopar Therapeutics. Biohaven's average media sentiment score of 0.33 beat Monopar Therapeutics' score of 0.00 indicating that Biohaven is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Monopar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is TSHA or MNPR more profitable?

Monopar Therapeutics' return on equity of -12.84% beat Taysha Gene Therapies' return on equity. Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies N/A -56.07% -40.16% Monopar Therapeutics N/A -12.84% -12.57%

Does the media favor TSHA or MNPR?

In the previous week, Taysha Gene Therapies had 3 more articles in the media than Monopar Therapeutics. MarketBeat recorded 5 mentions for Taysha Gene Therapies and 2 mentions for Monopar Therapeutics. Taysha Gene Therapies' average media sentiment score of 0.33 beat Monopar Therapeutics' score of 0.00 indicating that Taysha Gene Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Monopar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, GHRS or MNPR?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GH Research N/A N/A -$48.26M -$0.92 N/A Monopar Therapeutics N/A N/A -$13.72M -$1.90 N/A

Is GHRS or MNPR more profitable?

Monopar Therapeutics' return on equity of -12.84% beat GH Research's return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -19.36% -18.73% Monopar Therapeutics N/A -12.84% -12.57%

Does the media refer more to GHRS or MNPR?

In the previous week, GH Research and GH Research both had 2 articles in the media. GH Research's average media sentiment score of 0.29 beat Monopar Therapeutics' score of 0.00 indicating that GH Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Monopar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, SLS or MNPR?

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Monopar Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SELLAS Life Sciences Group N/A N/A -$26.86M -$0.23 N/A Monopar Therapeutics N/A N/A -$13.72M -$1.90 N/A

Is SLS or MNPR more profitable?

Monopar Therapeutics' return on equity of -12.84% beat SELLAS Life Sciences Group's return on equity. Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences Group N/A -47.12% -42.63% Monopar Therapeutics N/A -12.84% -12.57%

Does the media prefer SLS or MNPR?

In the previous week, SELLAS Life Sciences Group had 2 more articles in the media than Monopar Therapeutics. MarketBeat recorded 4 mentions for SELLAS Life Sciences Group and 2 mentions for Monopar Therapeutics. SELLAS Life Sciences Group's average media sentiment score of 0.49 beat Monopar Therapeutics' score of 0.00 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Monopar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MNPR or VCEL?

In the previous week, Monopar Therapeutics and Monopar Therapeutics both had 2 articles in the media. Monopar Therapeutics' average media sentiment score of 0.00 equaled Vericel'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vericel 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Monopar Therapeutics (MNPR) Competitors

$60.61 +1.13 (+1.90%)

Closing price 04:00 PM Eastern

Extended Trading

$60.63 +0.02 (+0.03%)

As of 04:10 PM Eastern

Compare

MNPR vs. BHVN, TSHA, GHRS, SLS, and VCEL

Should you buy Monopar Therapeutics stock or one of its competitors? MarketBeat compares Monopar Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Monopar Therapeutics include Biohaven (BHVN), Taysha Gene Therapies (TSHA), GH Research (GHRS), SELLAS Life Sciences Group (SLS), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry.

How does Monopar Therapeutics compare to Biohaven?

Biohaven (NYSE:BHVN) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

Monopar Therapeutics' return on equity of -12.84% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-866.46%	-137.99%
Monopar Therapeutics	N/A	-12.84%	-12.57%

Biohaven has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are owned by institutional investors. 13.8% of Biohaven shares are owned by insiders. Comparatively, 20.5% of Monopar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Biohaven currently has a consensus price target of $22.27, suggesting a potential upside of 100.26%. Monopar Therapeutics has a consensus price target of $107.91, suggesting a potential upside of 78.04%. Given Biohaven's higher possible upside, research analysts clearly believe Biohaven is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.71
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Biohaven had 1 more articles in the media than Monopar Therapeutics. MarketBeat recorded 3 mentions for Biohaven and 2 mentions for Monopar Therapeutics. Biohaven's average media sentiment score of 0.33 beat Monopar Therapeutics' score of 0.00 indicating that Biohaven is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Monopar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Monopar Therapeutics beats Biohaven on 8 of the 13 factors compared between the two stocks.

How does Monopar Therapeutics compare to Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ:TSHA) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Taysha Gene Therapies has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

Monopar Therapeutics has lower revenue, but higher earnings than Taysha Gene Therapies. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$7.47M	208.86	-$109M	-$0.38	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

In the previous week, Taysha Gene Therapies had 3 more articles in the media than Monopar Therapeutics. MarketBeat recorded 5 mentions for Taysha Gene Therapies and 2 mentions for Monopar Therapeutics. Taysha Gene Therapies' average media sentiment score of 0.33 beat Monopar Therapeutics' score of 0.00 indicating that Taysha Gene Therapies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Monopar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 3.8% of Taysha Gene Therapies shares are held by insiders. Comparatively, 20.5% of Monopar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Monopar Therapeutics' return on equity of -12.84% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.07%	-40.16%
Monopar Therapeutics	N/A	-12.84%	-12.57%

Taysha Gene Therapies presently has a consensus price target of $11.64, indicating a potential upside of 114.30%. Monopar Therapeutics has a consensus price target of $107.91, indicating a potential upside of 78.04%. Given Taysha Gene Therapies' higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Taysha Gene Therapies beats Monopar Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Monopar Therapeutics compare to GH Research?

GH Research (NASDAQ:GHRS) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

GH Research presently has a consensus target price of $40.38, suggesting a potential upside of 100.67%. Monopar Therapeutics has a consensus target price of $107.91, suggesting a potential upside of 78.04%. Given GH Research's higher possible upside, equities research analysts clearly believe GH Research is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Monopar Therapeutics' return on equity of -12.84% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
Monopar Therapeutics	N/A	-12.84%	-12.57%

56.9% of GH Research shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 20.5% of Monopar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Monopar Therapeutics is trading at a lower price-to-earnings ratio than GH Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

In the previous week, GH Research and GH Research both had 2 articles in the media. GH Research's average media sentiment score of 0.29 beat Monopar Therapeutics' score of 0.00 indicating that GH Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Monopar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GH Research has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

Summary

Monopar Therapeutics beats GH Research on 8 of the 13 factors compared between the two stocks.

How does Monopar Therapeutics compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

SELLAS Life Sciences Group presently has a consensus target price of $10.00, suggesting a potential upside of 25.31%. Monopar Therapeutics has a consensus target price of $107.91, suggesting a potential upside of 78.04%. Given Monopar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Monopar Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Comparatively, 20.5% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

SELLAS Life Sciences Group has a beta of 2.5, suggesting that its stock price is 150% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Monopar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

Monopar Therapeutics' return on equity of -12.84% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%
Monopar Therapeutics	N/A	-12.84%	-12.57%

In the previous week, SELLAS Life Sciences Group had 2 more articles in the media than Monopar Therapeutics. MarketBeat recorded 4 mentions for SELLAS Life Sciences Group and 2 mentions for Monopar Therapeutics. SELLAS Life Sciences Group's average media sentiment score of 0.49 beat Monopar Therapeutics' score of 0.00 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Monopar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Monopar Therapeutics beats SELLAS Life Sciences Group on 9 of the 14 factors compared between the two stocks.

How does Monopar Therapeutics compare to Vericel?

Monopar Therapeutics (NASDAQ:MNPR) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Monopar Therapeutics has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, Vericel has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

1.8% of Monopar Therapeutics shares are held by institutional investors. 20.5% of Monopar Therapeutics shares are held by company insiders. Comparatively, 7.6% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Vericel has a net margin of 7.35% compared to Monopar Therapeutics' net margin of 0.00%. Vericel's return on equity of 6.41% beat Monopar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
Vericel	7.35%	6.41%	4.61%

Vericel has higher revenue and earnings than Monopar Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
Vericel	$276.26M	6.61	$16.52M	$0.42	85.17

Monopar Therapeutics currently has a consensus price target of $107.91, suggesting a potential upside of 78.04%. Vericel has a consensus price target of $55.40, suggesting a potential upside of 54.88%. Given Monopar Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Monopar Therapeutics is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Monopar Therapeutics and Monopar Therapeutics both had 2 articles in the media. Monopar Therapeutics' average media sentiment score of 0.00 equaled Vericel'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vericel	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Monopar Therapeutics and Vericel tied by winning 7 of the 14 factors compared between the two stocks.

Get Monopar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNPR vs. The Competition

Export

Metric	Monopar Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$406.03M	$3.30B	$6.43B	$12.06B
Dividend Yield	N/A	2.31%	2.67%	5.56%
P/E Ratio	-31.90	18.94	23.77	23.75
Price / Sales	N/A	176.07	479.87	84.46
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	2.94	8.04	10.33	6.80
Net Income	-$13.72M	$23.89M	$3.57B	$337.51M
7 Day Performance	-5.89%	-6.00%	-1.43%	-2.59%
1 Month Performance	-4.67%	2.77%	3.33%	2.02%
1 Year Performance	63.33%	36.20%	23.49%	26.63%

Monopar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNPR Monopar Therapeutics	2.2677 of 5 stars	$60.61 +1.9%	$107.91 +78.0%	+60.3%	$406.03M	N/A	N/A	10	Analyst Upgrade
BHVN Biohaven	2.6716 of 5 stars	$10.13 -11.4%	$22.27 +119.9%	-36.2%	$1.72B	N/A	N/A	239
TSHA Taysha Gene Therapies	3.5438 of 5 stars	$5.69 -4.7%	$11.64 +104.5%	+93.7%	$1.72B	$9.77M	N/A	180
GHRS GH Research	2.3242 of 5 stars	$24.87 +0.2%	$40.38 +62.3%	+71.4%	$1.70B	N/A	N/A	10
SLS SELLAS Life Sciences Group	1.9464 of 5 stars	$8.33 -8.2%	$10.00 +20.0%	+411.2%	$1.69B	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNPR) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Monopar Therapeutics (MNPR) Competitors

MNPR vs. BHVN, TSHA, GHRS, SLS, and VCEL

How does Monopar Therapeutics compare to Biohaven?

Summary

How does Monopar Therapeutics compare to Taysha Gene Therapies?

Summary

How does Monopar Therapeutics compare to GH Research?

Summary

How does Monopar Therapeutics compare to SELLAS Life Sciences Group?

Summary

How does Monopar Therapeutics compare to Vericel?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR vs. The Competition

Monopar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Monopar Therapeutics (MNPR) Competitors

MNPR vs. BHVN, TSHA, GHRS, SLS, and VCEL

How does Monopar Therapeutics compare to Biohaven?

Which has preferable valuation and earnings, BHVN or MNPR?

Is BHVN or MNPR more profitable?

Which has more risk and volatility, BHVN or MNPR?

Do institutionals & insiders hold more shares of BHVN or MNPR?

Do analysts recommend BHVN or MNPR?

Does the media favor BHVN or MNPR?

Summary

How does Monopar Therapeutics compare to Taysha Gene Therapies?

Which has more risk & volatility, TSHA or MNPR?

Which has better earnings and valuation, TSHA or MNPR?

Does the media favor TSHA or MNPR?

Do institutionals and insiders believe in TSHA or MNPR?

Is TSHA or MNPR more profitable?

Do analysts recommend TSHA or MNPR?

Summary

How does Monopar Therapeutics compare to GH Research?

Do analysts prefer GHRS or MNPR?

Is GHRS or MNPR more profitable?

Do institutionals & insiders hold more shares of GHRS or MNPR?

Which has preferable earnings and valuation, GHRS or MNPR?

Does the media refer more to GHRS or MNPR?

Which has more risk and volatility, GHRS or MNPR?

Summary

How does Monopar Therapeutics compare to SELLAS Life Sciences Group?

Do analysts prefer SLS or MNPR?

Do institutionals and insiders have more ownership in SLS or MNPR?

Which has more risk & volatility, SLS or MNPR?

Which has higher valuation and earnings, SLS or MNPR?

Is SLS or MNPR more profitable?

Does the media prefer SLS or MNPR?

Summary

How does Monopar Therapeutics compare to Vericel?

Which has more volatility and risk, MNPR or VCEL?

Do institutionals & insiders have more ownership in MNPR or VCEL?

Is MNPR or VCEL more profitable?

Which has higher valuation & earnings, MNPR or VCEL?

Do analysts recommend MNPR or VCEL?

Does the media prefer MNPR or VCEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR vs. The Competition

Monopar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools